TRACON Pharmaceuticals Future Growth
Future criteria checks 0/6
TRACON Pharmaceuticals is forecast to grow earnings and revenue by 53.5% and 58.7% per annum respectively while EPS is expected to grow by 54.3% per annum.
Key information
53.5%
Earnings growth rate
54.3%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | 58.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 Apr 2024 |
Recent future growth updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 32 | -4 | N/A | 4 | 2 |
12/31/2025 | N/A | -21 | N/A | -13 | 2 |
12/31/2024 | N/A | -16 | N/A | -7 | 2 |
12/31/2023 | 12 | -4 | 4 | 4 | N/A |
9/30/2023 | 9 | -11 | 0 | 0 | N/A |
6/30/2023 | 9 | -28 | -22 | -22 | N/A |
3/31/2023 | N/A | -28 | -25 | -24 | N/A |
12/31/2022 | N/A | -29 | -26 | -26 | N/A |
9/30/2022 | N/A | -30 | -27 | -27 | N/A |
6/30/2022 | N/A | -30 | -28 | -28 | N/A |
3/31/2022 | 0 | -33 | -25 | -24 | N/A |
12/31/2021 | 0 | -29 | -23 | -23 | N/A |
9/30/2021 | 0 | -25 | -21 | -21 | N/A |
6/30/2021 | 0 | -22 | -17 | -17 | N/A |
3/31/2021 | N/A | -18 | -17 | -17 | N/A |
12/31/2020 | N/A | -17 | -17 | -17 | N/A |
9/30/2020 | N/A | -16 | -18 | -18 | N/A |
6/30/2020 | N/A | -18 | -20 | -20 | N/A |
3/31/2020 | N/A | -19 | -22 | -22 | N/A |
12/31/2019 | N/A | -23 | -24 | -24 | N/A |
9/30/2019 | N/A | -26 | -28 | -28 | N/A |
6/30/2019 | N/A | -30 | -27 | -27 | N/A |
3/31/2019 | N/A | -34 | -32 | -32 | N/A |
12/31/2018 | 3 | -35 | -31 | -31 | N/A |
9/30/2018 | 3 | -34 | -25 | -25 | N/A |
6/30/2018 | 10 | -24 | -17 | -17 | N/A |
3/31/2018 | 11 | -20 | -12 | -12 | N/A |
12/31/2017 | 9 | -19 | -13 | -13 | N/A |
9/30/2017 | 9 | -19 | N/A | -17 | N/A |
6/30/2017 | 3 | -26 | N/A | -23 | N/A |
3/31/2017 | 3 | -28 | N/A | -28 | N/A |
12/31/2016 | 3 | -27 | N/A | -27 | N/A |
9/30/2016 | 4 | -32 | N/A | -29 | N/A |
6/30/2016 | 5 | -32 | N/A | -27 | N/A |
3/31/2016 | 8 | -27 | N/A | -21 | N/A |
12/31/2015 | 8 | -24 | N/A | -19 | N/A |
9/30/2015 | 8 | -16 | N/A | -15 | N/A |
6/30/2015 | 8 | -12 | N/A | -13 | N/A |
3/31/2015 | 4 | -10 | N/A | -11 | N/A |
12/31/2014 | 4 | -7 | N/A | 2 | N/A |
9/30/2014 | 3 | -7 | N/A | 3 | N/A |
6/30/2014 | 1 | -7 | N/A | 3 | N/A |
3/31/2014 | 0 | -8 | N/A | 3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCON is forecast to have no revenue next year.
High Growth Revenue: TCON is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TCON's Return on Equity is forecast to be high in 3 years time